curevac biontech - Search News

News

CureVac, BioNTech

Reuters on MSN · 2d

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

The Wall Street Journal on MSN · 2d

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

The plan is to bring the two biotech companies together to develop transformative cancer treatments, BioNTech said.

Bloomberg · 2d

BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will boost its growing oncology business.

GlobalData on MSN2d

BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

2don MSN

BioNTech kauft CureVac für $1,25 Mrd., stärkt Onkologiegeschäft

BioNTech hat vereinbart, den ehemaligen Corona-Impfstoffkonkurrenten CureVac für rund 1,25 Milliarden Dollar (1,08 Milliarden ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results